

Anti-IFNAR1 Reference Antibody (Faralimomab)
Recombinant Antibody
Catalog # APR10945

Specification

Anti-IFNAR1 Reference Antibody (Faralimomab) - Product Information

Application	FC, E, FTA
Primary Accession	P17181
Reactivity	Human
Clonality	Monoclonal
Isotype	mIgG1
Calculated MW	145.34 KDa

Anti-IFNAR1 Reference Antibody (Faralimomab) - Additional Information

Target/Specificity
IFNAR1

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-IFNAR1 Reference Antibody (Faralimomab) - Protein Information

Name IFNAR1

Synonyms IFNAR

Function

Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed:<a href="<http://www.uniprot.org/citations/2153461>">2153461, PubMed:<a href="<http://www.uniprot.org/citations/7813427>">7813427, PubMed:<a href="<http://www.uniprot.org/citations/10049744>">10049744, PubMed:<a href="<http://www.uniprot.org/citations/14532120>">14532120, PubMed:[2153461](#), PubMed:[7813427](#), PubMed:[10049744](#), PubMed:[14532120](#)

href="http://www.uniprot.org/citations/15337770" target="_blank">>15337770, PubMed:>24075985, PubMed:>21854986, PubMed:>31270247, PubMed:>33252644, PubMed:>35442418). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed:>7665574, PubMed:>10049744, PubMed:>21854986). Mechanistically, type I interferon- binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed:>7813427, PubMed:>7665574, PubMed:>21854986, PubMed:>32972995). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (PubMed:>7813427, PubMed:>7526154, PubMed:>7665574, PubMed:>21854986, PubMed:>32972995). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed:>7813427, PubMed:>7665574, PubMed:>9121453, PubMed:>19561067, PubMed:>21854986, PubMed:>32972995). Can also act independently of IFNAR2: form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity).

Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Late endosome. Lysosome.
Note=Interferon binding triggers internalization of the receptor from the cell membrane into endosomes and then into lysosomes.

Tissue Location

IFN receptors are present in all tissues and even on the surface of most IFN-resistant cells. Isoform 1, isoform 2 and isoform 3 are expressed in the IFN-alpha sensitive myeloma cell line U266B1. Isoform 2 and isoform 3 are expressed in the IFN-alpha resistant myeloma cell line U266R. Isoform 1 is not expressed in IFN- alpha resistant myeloma cell line U266R.


Anti-IFNAR1 Reference Antibody (Faralimomab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-IFNAR1 Reference Antibody (Faralimomab) - Images



Anti-IFNAR1 Reference Antibody (Faralimomab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IFNAR1 Reference Antibody (Faralimomab) is more than 99.35% ,determined by SEC-HPLC.